Previous 10 | Next 10 |
2024-03-15 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-14 17:34:14 ET Summary Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development...
2024-03-13 13:53:08 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call P...
− Pre-Specified Interim Analysis Shows Positive Safety and Efficacy Results; Mezagitamab Safe and Well Tolerated − Takeda Intends to Initiate a Global Phase 3 Trial of Mezagitamab in Patients with Primary Immune Thrombocytopenia in Fiscal Year 2024 − ...
2024-03-12 13:05:20 ET Summary Pfizer's share price has stabilized since the company provided 2024 revenue and EPS guidance in late 2023. The success of Adcetris in a trial for relapsed/refractory DLBCL is a positive step for Pfizer's oncology pipeline and the first win since the ...
2024-03-12 07:45:49 ET More on Pfizer Pfizer: A Strong Buy Trading Below A 10 P/E Ratio Pfizer Inc. (PFE) TD Cowen 44th Annual Health Care Conference 6%-Yielding Pfizer Is An Ultra-Deep-Value Gem In An Expensive Market Biden to push for expanding Medicare dru...
2024-03-05 09:54:23 ET Summary Takeda wins FDA approval for the first oral treatment for Eosinophilic esophagitis (EoE) in the US. The market size for EoE is expected to reach $941.8 million by 2031. Takeda's new CFO, Milano Furuta, will focus on growth and increasing sharehol...
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to Help Protec...
Championing Rare Voices on Rare Disease Day Canada NewsWire 1 in 12 Canadians will be impacted by rare disease in their lifetime 1 I Am Number 12 campaign continues to drive action for rare disease community TORONTO , Feb. 26, 2024 /CNW/ - ...
2024-02-13 01:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade Takeda ( TSE:4502/N...
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA ® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless o...
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older Canada NewsWire HyQvia®, which may be administered at home, will provide children and adolesc...